Practice Economics

Cigna CEO David Cordani: ACA marketplace is still in ‘version 1.0’


 

References

If you have an individual with a chronic disease, say asthma, you can have a program that is passive: If they want to enroll in a care management plan, they can. Or they can be incented to enroll. Or you can have a plan that is binary: If [you] have that [condition] [you] have to be in that [care management] program. Those are all choices. What we know is if [a patient is] asthmatic and more actively managed, the health outcomes and therefore the affordability can be quite different. This is a case where if you have a chronic illness, you need to be in a management program. We know the quality outcomes will be better and cost outcomes will be more sustainable.

In late December, Cigna will stop paying brokers commissions if they sell gold-level individual plans, which cover more costs than do the less expensive bronze and silver level plans. What is Cigna’s concern with gold products?

Adverse selection. [It’s not that policyholders] are necessarily older or sicker. The whole way the benefits are configured and the way marketplace is working – the performance of those plans – is much less reasonable than all the other plans.

Either there will be more flexibility to configure them in a way to make them sustainable or there won’t be gold plans.

So is Cigna staying in the market?

We’re in for 2016.

How about 2017?

We haven’t made a comment relative to 2017. We view 2014, 2015, and 2016 as version 1.0.

Kaiser Health News is a national health policy news service that is part of the nonpartisan Henry K. Kaiser Family Foundation.

Pages

Recommended Reading

HHS: Remaining uninsured worry about costs of coverage
MDedge Hematology and Oncology
ACA insurance networks lack specialist coverage
MDedge Hematology and Oncology
Healthcare.gov: Premiums to jump in 8 states
MDedge Hematology and Oncology
Small businesses snub Obamacare’s SHOP exchange
MDedge Hematology and Oncology
Supreme Court agrees to hear ACA contraceptive mandate opt-out challenge
MDedge Hematology and Oncology
Senate panel targets drug prices during FDA commissioner nomination hearing
MDedge Hematology and Oncology
UnitedHealth warns of marketplace exit: Start of a trend or push for White House action?
MDedge Hematology and Oncology
After 3 years of decline, hospital injury rates plateau, report finds
MDedge Hematology and Oncology
Health spending growth soars after years of low growth
MDedge Hematology and Oncology
Senate votes to gut ACA, defund Planned Parenthood
MDedge Hematology and Oncology